Takeda Alofisel Clinical Remission Rate At Six-Months in Crohn's

 Takeda Pharmaceutical Co Ltd 

TAK +0.62%

 (Get Free Alerts for TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel).

• The study demonstrated clinical remission in 65% of patients in both cohorts evaluated at six months, with Crohn's disease (CD) and complex perianal fistulas.
• Data were presented at the European Crohn's and Colitis Organisation (ECCO) 2022 Congress.
• Clinical response was observed in 73% (57/78) and 74% (51/69) of patients in the All Treated (AT) and Treated Per Protocol (PP) cohorts, respectively.
• Changes in CD activity post-treatment were minimal. Of the 205 patients with complete treatment data, 20% (41/205) had one or more adverse events, and 9.3% (19/205) had one or more serious adverse events.
• There were no reports of ectopic tissue formation and no deaths.

https://www.benzinga.com/general/biotech/22/02/25715384/real-world-analysis-show-takedas-alofisel-clinical-remission-rate-at-six-months